Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EBIT (2020 - 2026)

Rani Therapeutics Holdings' EBIT history spans 7 years, with the latest figure at -$8.3 million for Q1 2026.

  • On a quarterly basis, EBIT rose 30.58% to -$8.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$34.6 million, a 32.48% increase, with the full-year FY2025 number at -$38.3 million, up 28.14% from a year prior.
  • EBIT came in at -$8.3 million for Q1 2026, up from -$8.5 million in the prior quarter.
  • The five-year high for EBIT was -$7.3 million in Q3 2025, with the low at -$18.3 million in Q2 2023.
  • Historically, EBIT has averaged -$13.5 million across 5 years, with a median of -$13.8 million in 2022.
  • Biggest five-year swings in EBIT: plummeted 201.39% in 2022 and later surged 42.94% in 2025.
  • Year by year, EBIT stood at -$17.5 million in 2022, then grew by 23.16% to -$13.4 million in 2023, then fell by 11.34% to -$15.0 million in 2024, then surged by 42.94% to -$8.5 million in 2025, then rose by 2.3% to -$8.3 million in 2026.
  • Business Quant data shows EBIT for RANI at -$8.3 million in Q1 2026, -$8.5 million in Q4 2025, and -$7.3 million in Q3 2025.